
Hemophilia Treatment Market by Product Type (Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates), Disease Indication (Hemophilia A, Hemophilia B, Polyethylene), Distribution - Global Forecast 2024-2030
Description
Hemophilia Treatment Market by Product Type (Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates), Disease Indication (Hemophilia A, Hemophilia B, Polyethylene), Distribution - Global Forecast 2024-2030
The Hemophilia Treatment Market size was estimated at USD 14.32 billion in 2023 and expected to reach USD 15.23 billion in 2024, at a CAGR 6.45% to reach USD 22.18 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Hemophilia Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hemophilia Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Hemophilia Treatment Market, highlighting leading vendors and their innovative profiles. These include Aptevo Therapeutics, Biogen Inc., Biotest AG, Bioverativ Inc., CSL Behring, F. Hoffmann-La Roche AG, Ferring B.V., Genentech, Inc., Grifols SA, Kedrion S.P.A, LÄKEMEDEL AB, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited.
Market Segmentation & Coverage
This research report categorizes the Hemophilia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
Product Type
Antifibrinolytic Agents
Desmopressin
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Disease Indication
Hemophilia A
Hemophilia B
Polyethylene
Distribution
E-commerce
Hospital Pharmacies
Retail Pharmacies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Hemophilia Treatment Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hemophilia Treatment Market?
3. What are the technology trends and regulatory frameworks in the Hemophilia Treatment Market?
4. What is the market share of the leading vendors in the Hemophilia Treatment Market?
5. Which modes and strategic moves are suitable for entering the Hemophilia Treatment Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Hemophilia Treatment Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing number of cases of hemophilia
- 5.1.1.2. Rising diagnostic and awareness related to Hemophilia
- 5.1.1.3. Increasing demand for recombinant and plasma-derived factor VIII and factor IX
- 5.1.2. Restraints
- 5.1.2.1. Serious adverse effects associated with plasma-derived products
- 5.1.3. Opportunities
- 5.1.3.1. Increased diagnosis rate and rise in the use of prophylactic treatment
- 5.1.3.2. Emerging advances and innovations in hemophilia treatment
- 5.1.4. Challenges
- 5.1.4.1. High cost of recombinant products and stringent government regulations
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Hemophilia Treatment Market, by Product Type
- 6.1. Introduction
- 6.2. Antifibrinolytic Agents
- 6.3. Desmopressin
- 6.4. Plasma Derived Coagulation Factor Concentrates
- 6.5. Recombinant Coagulation Factor Concentrates
- 7. Hemophilia Treatment Market, by Disease Indication
- 7.1. Introduction
- 7.2. Hemophilia A
- 7.3. Hemophilia B
- 7.4. Polyethylene
- 8. Hemophilia Treatment Market, by Distribution
- 8.1. Introduction
- 8.2. E-commerce
- 8.3. Hospital Pharmacies
- 8.4. Retail Pharmacies
- 9. Americas Hemophilia Treatment Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Hemophilia Treatment Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Hemophilia Treatment Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Aptevo Therapeutics
- 13.1.2. Biogen Inc.
- 13.1.3. Biotest AG
- 13.1.4. Bioverativ Inc.
- 13.1.5. CSL Behring
- 13.1.6. F. Hoffmann-La Roche AG
- 13.1.7. Ferring B.V.
- 13.1.8. Genentech, Inc.
- 13.1.9. Grifols SA
- 13.1.10. Kedrion S.P.A
- 13.1.11. LÄKEMEDEL AB
- 13.1.12. Novo Nordisk A/S
- 13.1.13. Octapharma AG
- 13.1.14. Pfizer Inc.
- 13.1.15. Takeda Pharmaceutical Company Limited
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. HEMOPHILIA TREATMENT MARKET RESEARCH PROCESS
- FIGURE 2. HEMOPHILIA TREATMENT MARKET SIZE, 2023 VS 2030
- FIGURE 3. HEMOPHILIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. HEMOPHILIA TREATMENT MARKET DYNAMICS
- FIGURE 7. HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
- FIGURE 8. HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
- FIGURE 10. HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
- FIGURE 12. HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.